Last updated on July 2020

A First-in-human Study Using BDC-1001 in Advanced and HER2-Expressing Solid Tumors


Brief description of study

A first-in-human study using BDC-1001 in HER2 expressing advanced malignancies

Detailed Study Description

This study has four parts. Part 1 is a dose escalation of BDC-1001 as a single agent to determine the maximum tolerated dose (MTD) recommended for Part 3 and Phase 2 (RP2D). In Part 3, the selected dose will be administered as monotherapy to patients with selected advanced malignancies. Part 2 is a dose escalation of BDC-1001 in combination with pembrolizumab to determine the maximum tolerated dose (MTD) recommended for Part 4 and Phase 2 (RP2D). In Part 4, the selected dose will be administered in combination with pembrolizumab to patients with selected advanced malignancies.

Clinical Study Identifier: NCT04278144

Find a site near you

Start Over

Bolt Investigative Site

Grand Rapids, MI United States
  Connect »

Bolt Investigative Site

San Antonio, TX United States
  Connect »

Bolt Investigative Site

Houston, TX United States
  Connect »

Bolt Investigative Site

Pittsburgh, PA United States
  Connect »

Bolt Investigative Site

Oklahoma City, OK United States
  Connect »

Bolt Investigative Site

Fairfax, VA United States
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.